Jefferies Financial Group Lowers Agilent Technologies (NYSE:A) Price Target to $116.00

Agilent Technologies (NYSE:A) had its target price cut by equities researchers at Jefferies Financial Group from $135.00 to $116.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “hold” rating on the medical research company’s stock. Jefferies Financial Group’s target price suggests a potential upside of 16.44% from the stock’s current price.

Several other analysts have also weighed in on A. TD Cowen lifted their target price on shares of Agilent Technologies to $135.00 and gave the company a “buy” rating in a research note on Thursday, April 10th. Robert W. Baird dropped their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Barclays decreased their target price on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Finally, Wells Fargo & Company dropped their target price on Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating on the stock in a research report on Thursday. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $143.00.

Agilent Technologies Stock Down 2.8 %

A traded down $2.86 on Monday, reaching $99.62. 550,253 shares of the company traded hands, compared to its average volume of 1,854,084. The stock’s 50 day moving average price is $119.55 and its 200-day moving average price is $132.31. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. Agilent Technologies has a 52-week low of $96.43 and a 52-week high of $155.35. The company has a market cap of $28.40 billion, a price-to-earnings ratio of 22.90, a PEG ratio of 2.89 and a beta of 1.19.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The business had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. On average, sell-side analysts expect that Agilent Technologies will post 5.54 EPS for the current fiscal year.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Rodney Gonsalves sold 1,908 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the sale, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. The trade was a 8.05 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,638 shares of company stock worth $731,229.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in A. CKW Financial Group boosted its stake in shares of Agilent Technologies by 114.9% during the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock worth $25,000 after purchasing an additional 100 shares during the period. Global X Japan Co. Ltd. raised its stake in Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after buying an additional 116 shares in the last quarter. Redwood Park Advisors LLC bought a new stake in Agilent Technologies during the fourth quarter valued at about $27,000. Lee Danner & Bass Inc. bought a new position in shares of Agilent Technologies during the 4th quarter worth approximately $29,000. Finally, Whipplewood Advisors LLC boosted its position in shares of Agilent Technologies by 286.2% in the 1st quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock worth $29,000 after purchasing an additional 186 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.